Abstract Number: 2519 • 2019 ACR/ARP Annual Meeting
Cenerimod, a Potent, Selective and Orally Active Sphingosine 1-phosphate Receptor 1 Modulator, Reduced Blood Antibody-secreting Cells in Patients with SLE
Background/Purpose: SLE is an autoimmune disease driven by autoreactive T and B lymphocytes. Lymphocytes infiltrate self-antigen expressing tissues, in which tertiary lymphoid structures are often…Abstract Number: 2520 • 2019 ACR/ARP Annual Meeting
Treatment of SLE Patients with the Immunoproteasome Inhibitor KZR-616: Results from the First 3 Cohorts of an Open-Label Phase 1b Dose Escalation Trial
Background/Purpose: Nonspecific proteasome inhibitors, eg, bortezomib (BTZ), target both the constitutive and immuno- proteasome and are approved for the treatment of multiple myeloma. While BTZ…Abstract Number: 2521 • 2019 ACR/ARP Annual Meeting
Rituximab Treatment Is Not Associated with Increased Risk of Infection or Mortality in Refractory SLE Patients: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)
Background/Purpose: Mortality in Systemic Lupus Erythematosus (SLE) is increased compared to the general population. We sought to investigate mortality rates and associated factors in a…Abstract Number: 2522 • 2019 ACR/ARP Annual Meeting
Frequency and Early Prediction of Hydroxychloroquine Induced Retinopathy in SLE
Background/Purpose: In 2016, the American Academy of Ophthalmology (AAO) published recommendations designed to reduce hydroxychloroquine induced retinopathy via early detection and reduction of hydroxychloroquine dosing…Abstract Number: 2523 • 2019 ACR/ARP Annual Meeting
Contemporary Prescription Opioid Use and Predictors Among Patients with Systemic Lupus Erythematosus
Background/Purpose: SLE is a complex illness that can be associated with chronic pain. In recent years, an international opioid epidemic has become a major public…Abstract Number: 2524 • 2019 ACR/ARP Annual Meeting
24-Month Outcomes Associated with Belimumab in Black/African-American Patients with Systemic Lupus Erythematosus in a Clinical Practice Setting in the United States
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by diverse clinical manifestations and organ damage accrual. Black/African-American (B/AA) race is associated with…Abstract Number: 2525 • 2019 ACR/ARP Annual Meeting
Within-Trial Cost Analysis of Flares from a Phase 3 Clinical Trial Evaluating Subcutaneous Belimumab for the Treatment of Systemic Lupus Erythematosus
Background/Purpose: SLE is a chronic autoimmune disease characterized by diverse clinical manifestations and flares associated with organ damage, resulting in substantial short-term management costs. Results…Abstract Number: 2526 • 2019 ACR/ARP Annual Meeting
Antimalarial Agents Improve Physical Functioning in Patients with Systemic Lupus Erythematosus
Background/Purpose: Patients with systemic lupus erythematosus (SLE) suffer an impaired health-related quality of life (HRQoL), and the majority of them experience fatigue as a major…Abstract Number: 2527 • 2019 ACR/ARP Annual Meeting
Cytokine and Autoantibody Profiles During Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
Background/Purpose: The anti-BAFF monoclonal belimumab is approved for the treatment of systemic lupus erythematosus (SLE) since 2011. Effects of belimumab on anti-double stranded (ds)DNA levels,…Abstract Number: 2528 • 2019 ACR/ARP Annual Meeting
Effect of Additional Administration of HCQ on Pro-inflammatory Cytokine Expression, Especially in Lupus Nephritis
Background/Purpose: Hydroxychloroquine(HCQ) is recommended for all patients with SLE in EULAR recommendation 2019, however, there are not enough data about the effect of additional HCQ…Abstract Number: 2529 • 2019 ACR/ARP Annual Meeting
Safety of Chloroquine and Hydroxychloroquine During Pregnancy: A Systematic Review and Meta-Analysis
Background/Purpose: Chloroquine (CQ) and Hydroxychloroquine (HCQ) have been used for years during pregnancy for multiple indications (malaria prevention, autoimmune disorders, etc.…). Recently, some countries face…Abstract Number: 2530 • 2019 ACR/ARP Annual Meeting
Safety, Pharmacokinetics, and Pharmacodynamics of a Lyophilized Drug Product of KZR-616, a Selective Inhibitor of the Immunoproteasome
Background/Purpose: KZR-616, a first-in-class selective inhibitor of the immunoproteasome, is being evaluated for the treatment of multiple autoimmune diseases, including LN and PM/DM. At 30…Abstract Number: 2531 • 2019 ACR/ARP Annual Meeting
Low Vitamin D Is Associated with Miscarriage and Preterm Birth in SLE with a U-shaped Relationship
Background/Purpose: In the general population, low vitamin D has been associated with adverse pregnancy outcomes including preterm birth, pre-eclampsia and small for gestational age. In…Abstract Number: 2532 • 2019 ACR/ARP Annual Meeting
Effect of Treatment on Antiphospholipid Antibodies in SLE
Background/Purpose: Unlike primary antiphospholipid syndrome patients, most SLE patients with antiphospholipid antibodies are on one or more treatments for their SLE that might affect levels…Abstract Number: 2533 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Increases Low C3 in SLE
Background/Purpose: Hydroxychloroquine is considered an immunomodulatory that does not affect serology. Hydroxychloroquine (HCQ) was recently introduced into Japan. In SLE patients who started hydroxychloroquine, there…
ACR Meeting Abstracts